PSA monitoring as effective as treatment for prostate cancer

Men with prostate cancer who have PSA monitoring rather than active treatment have fewer side effects and no greater mortality risk after 10 years, a landmark UK study shows. 

In a randomised trial of 1643 men diagnosed with prostate cancer, researchers found that all had a 1% risk of prostate cancer death at 10 years, regardless of whether they had active monitoring, radical prostatectomy or radiotherapy. 

Men who had surgery or radiotherapy had disease progression rates of about half of those in the active